Equities

Zhejiang Cheng Yi Pharmaceutical Co Ltd

603811:SHH

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.21
  • Today's Change-0.08 / -1.27%
  • Shares traded3.92m
  • 1 Year change-46.33%
  • Beta0.9536
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Cheng Yi Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and sales of bulk pharmaceutical chemicals of chemical medicine and preparations. The Company’s products are on the spectrum from arthritis, dieresis to anti-virus and anti-tumor. The main products include bulk pharmaceutical chemicals, injections, capsules, intermediates and others.

  • Revenue in CNY (TTM)706.56m
  • Net income in CNY148.76m
  • Incorporated2001
  • Employees738.00
  • Location
    Zhejiang Cheng Yi Pharmaceutical Co LtdNo. 118 Huagong Road, Dongtou DistrictSHANGHAI 201100ChinaCHN
  • Phone+86 2 133283295
  • Fax+86 2 133283305
  • Websitehttp://www.chengyipharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang Cheng Yi Pharmaceutical Co Ltd706.56m148.76m2.06bn738.0013.891.71--2.910.45290.45292.153.680.39382.1111.86957,393.108.2612.0110.5514.7565.4269.7920.9822.840.7041--0.241636.442.544.240.812910.94-23.5612.84
Novoprotein Scientific Inc138.16m-8.42m2.08bn579.00--0.9692--15.09-0.12-0.121.9730.650.060.5722.01238,613.90-0.3661---0.3779--64.49---6.10--22.83--0.034---42.09---85.84------
Ginwa Enterprise Group Inc556.00m-36.47m2.16bn553.00--1.36--3.88-0.0977-0.09771.494.250.29844.835.591,005,424.00-1.960.3641-2.250.414175.4573.64-6.561.152.66-0.0780.0698124.25-2.41-5.37-228.19--61.66--
Ningbo Menovo Pharmaceutical Co Ltd1.24bn-326.25k2.19bn2.35k7,049.301.03--1.76-0.0323-0.03235.329.670.28021.295.28527,886.100.06614.940.09897.8329.1635.390.235913.710.781.890.417610.78-16.517.46-96.58-34.53-6.03-32.54
Shanghai Fudan Forward S&T Co Ltd648.79m7.38m2.19bn1.36k291.442.78--3.380.0110.0110.95081.150.37780.62157.41476,003.600.4294-0.87810.7407-1.5338.3043.221.14-1.850.4148-4.480.395---13.86-7.58196.17-32.57-13.88--
Data as of Sep 13 2024. Currency figures normalised to Zhejiang Cheng Yi Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

7.96%Per cent of shares held by top holders
HolderShares% Held
China Post & Capital Fund Management Co., Ltd.as of 31 Dec 20235.00m1.53%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20234.48m1.37%
Penghua Fund Management Co., Ltd.as of 31 Dec 20233.95m1.21%
Great Wall Fund Management Co., Ltd.as of 31 Dec 20232.39m0.73%
China Merchants Fund Management Co., Ltd.as of 31 Dec 20232.34m0.71%
Rongtong Fund Management Co., Ltd.as of 31 Dec 20232.08m0.64%
Cinda Fund Management Co. Ltd.as of 31 Dec 20232.03m0.62%
GF Fund Management Co., Ltd.as of 31 Dec 20231.77m0.54%
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 20231.04m0.32%
China Southern Asset Management Co., Ltd.as of 31 Dec 2023976.58k0.30%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.